FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

J 2022

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

DOLEZEL, Martin, Marek SLÁVIK, Tomas BLAZEK, Tomáš KAZDA, Pavel KORANDA et. al.

Základní údaje

Originální název

FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer

Autoři

DOLEZEL, Martin (203 Česká republika), Marek SLÁVIK (703 Slovensko, garant, domácí), Tomas BLAZEK (203 Česká republika), Tomáš KAZDA (203 Česká republika, domácí), Pavel KORANDA (203 Česká republika), Lucia VEVERKOVA (203 Česká republika), Petr BURKOŇ (203 Česká republika, domácí) a Jakub CVEK (203 Česká republika)

Vydání

Journal of Personalized Medicine, Basel, MDPI, 2022, 2075-4426

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30224 Radiology, nuclear medicine and medical imaging

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.508 v roce 2021

Kód RIV

RIV/00216224:14110/22:00128261

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3390/jpm12081245

UT WoS

000845752300001

Klíčová slova anglicky

head and neck cancer; adaptive radiotherapy; FMISO

Štítky

14110812, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 10:19, Mgr. Tereza Miškechová

Anotace

V originále

Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the "one dose fits all" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.

Citovat

DOLEZEL, Martin, Marek SLÁVIK, Tomas BLAZEK, Tomáš KAZDA, Pavel KORANDA, Lucia VEVERKOVA, Petr BURKOŇ a Jakub CVEK. FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. Journal of Personalized Medicine. Basel: MDPI, 2022, roč. 12, č. 8, s. 1-12. ISSN 2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm12081245.

@article{2249580,
   author = {Dolezel, Martin and Slávik, Marek and Blazek, Tomas and Kazda, Tomáš and Koranda, Pavel and Veverkova, Lucia and Burkoň, Petr and Cvek, Jakub},
   article_location = {Basel},
   article_number = {8},
   doi = {http://dx.doi.org/10.3390/jpm12081245},
   keywords = {head and neck cancer; adaptive radiotherapy; FMISO},
   language = {eng},
   issn = {2075-4426},
   journal = {Journal of Personalized Medicine},
   title = {FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer},
   url = {https://www.mdpi.com/2075-4426/12/8/1245},
   volume = {12},
   year = {2022}
}

TY  - JOUR
ID  - 2249580
AU  - Dolezel, Martin - Slávik, Marek - Blazek, Tomas - Kazda, Tomáš - Koranda, Pavel - Veverkova, Lucia - Burkoň, Petr - Cvek, Jakub
PY  - 2022
TI  - FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer
JF  - Journal of Personalized Medicine
VL  - 12
IS  - 8
SP  - 1-12
EP  - 1-12
PB  - MDPI
SN  - 20754426
KW  - head and neck cancer
KW  - adaptive radiotherapy
KW  - FMISO
UR  - https://www.mdpi.com/2075-4426/12/8/1245
N2  - Concurrent chemoradiotherapy represents one of the most used strategies in the curative treatment of patients with head and neck (HNC) cancer. Locoregional failure is the predominant recurrence pattern. Tumor hypoxia belongs to the main cause of treatment failure. Positron emission tomography (PET) using hypoxia radiotracers has been studied extensively and has proven its feasibility and reproducibility to detect tumor hypoxia. A number of studies confirmed that the uptake of FMISO in the recurrent region is significantly higher than that in the non-recurrent region. The escalation of dose to hypoxic tumors may improve outcomes. The technical feasibility of optimizing radiotherapeutic plans has been well documented. To define the hypoxic tumour volume, there are two main approaches: dose painting by contour (DPBC) or by number (DPBN) based on PET images. Despite amazing technological advances, precision in target coverage, and surrounding tissue sparring, radiation oncology is still not considered a targeted treatment if the "one dose fits all" approach is used. Using FMISO and other hypoxia tracers may be an important step for individualizing radiation treatment and together with future radiomic principles and a possible genome-based adjusting dose, will move radiation oncology into the precise and personalized era.
ER  -

DOLEZEL, Martin, Marek SLÁVIK, Tomas BLAZEK, Tomáš KAZDA, Pavel KORANDA, Lucia VEVERKOVA, Petr BURKOŇ a Jakub CVEK. FMISO-Based Adaptive Radiotherapy in Head and Neck Cancer. \textit{Journal of Personalized Medicine}. Basel: MDPI, 2022, roč.~12, č.~8, s.~1-12. ISSN~2075-4426. Dostupné z: https://dx.doi.org/10.3390/jpm12081245.

Podrobný výpis o publikaci